Key Highlights
- Third-quarter 2026 Revenue was USD 18.4 million, up 6.8% from USD 17.2 million, which management called the best third quarter in company history, while nine-month revenue rose to USD 55.7 million.
- Trailing 12-month average selling price for AVISE CTD reached a record USD 451 per test, up USD 10 year over year and the 14th consecutive quarter of improvement, per the call.
- The net loss narrowed to USD 6.3 million, or USD 0.25 per share, from USD 7.1 million, or USD 0.31, while the adjusted EBITDA loss was USD 1.9 million in both quarters.
- Cash and equivalents were just over USD 28 million at September 30, 2026, and management reiterated 2026 revenue guidance of USD 72 million to USD 75 million.
Price Gains Carry a Volume-Light Quarter
Exagen (NASDAQ:XGN) reported third-quarter results on November 10, 2026, for the quarter ended September 30, 2026. The company sells autoimmune diagnostics, led by the AVISE CTD test for connective tissue disease, which made up 90% of nine-month revenue. Revenue was USD 18.4 million against USD 17.2 million. Management said AVISE CTD Volume grew 2%, in line with seasonality, so price did much of the work. Trailing 12-month average selling price was USD 451, and about USD 800,000 was collected from claims older than 360 days. Ordering physicians rose 5%, and territories grew to 45 from 42.
Margins, Operating Costs and an Unchanged Adjusted Loss
Gross profit was USD 10.84 million, a Margin of about 58.8% (calculated), compared with USD 10.08 million, or about 58.4%. Management described the margin as just under 59%. Total operating expenses rose to USD 15.2 million from USD 13.2 million, including more than USD 600,000 of added stock-based compensation and a one-time in-process research charge of roughly USD 600,000 tied to a strategic investment. Excluding both, operating expenses were USD 13.4 million, up about 6%. Loss from operations widened to USD 4.4 million from USD 3.1 million, yet the net loss narrowed. Pharma Services revenue topped USD 900,000, with a Backlog of about USD 5.5 million.
Guidance, Myositis Launch and Balance Sheet Funding
The company reiterated full-year revenue guidance of USD 72 million to USD 75 million, assuming high single-digit volume growth and mid-single-digit price growth versus the fourth-quarter 2025 exit rate. A myositis test is planned for early 2027, with a validation package due to the New York State Department of Health by the end of January. Cash rose USD 3.5 million in the quarter, helped by about USD 6.5 million from an at-the-market stock program, which sells new shares and dilutes holders. After quarter end it drew USD 5 million of a USD 10 million Debt tranche, lifting pro forma cash to just over USD 33 million. A December 15 webcast will cover the pipeline.
Where Things Stand
Probably, though not without limits. Exagen (NASDAQ:XGN) has raised trailing average selling price for 14 straight quarters to USD 451, but management itself said quarterly gains from revenue cycle work can be variable and that the target of at least 50% of the Medicare rate, about USD 600 to USD 650 per test, will take time. Volume grew only 2% in the quarter, losses continue and Equity sales add dilution. Next markers are fourth-quarter seasonality, the myositis submission by January, the December 15 webcast and whether full-year revenue lands within USD 72 million to USD 75 million.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...